參考文獻/References:
[1] ROSEN G,MARCOVE RC,CAPARROS B,et al.Primary osteogenic sarcoma:the rationale for preoperative chemotherapy and delayed surgery[J].Cancer,1979,43(6):2163-2177.
[2] 吳宏增,王進,馮和林.自噬與骨肉瘤的研究進展[J].腫瘤防治研究,2017,44(2):153-156.
[3] 易生輝,秦剛,黃肖華,等.骨肉瘤的治療進展[J].醫(yī)學綜述,2017,19(8):1529-1532.
[4] 李奕緜,常君麗,施杞,等.骨肉瘤免疫治療的研究現(xiàn)狀[J].癌癥進展,2017,15(6):605-608.
[5] HARTL DL.遺傳學——基因和基因組分析[M].8版.北京:科學出版社,2015:1.
[6] DANESHMANDI S,POURFATHOLLAH AA,KARIMI MH,et al.PDL-1/PDL-2 blockade in mice dendritic cells by RNAi techniques to induce antitumor immunity[J]. Immunotherapy,2015,7(11):1145-1158.
[7] 林洪生,張英.從“扶正培本”到“固本清源”——中醫(yī)藥治療腫瘤理論的傳承與創(chuàng)新[J].中醫(yī)雜志,2016,57(4):295-298.
[8] 劉智勤,陳鵲汀,李巖,等.肉蓯蓉對化療荷瘤小鼠增效減毒作用的研究[J].時珍國醫(yī)國藥,2011,22(4):1037-1038.
[9] 楊潔文,劉云霞,姚勇偉,等.參麥注射液對骨肉瘤患者大劑量化療后免疫功能的調(diào)節(jié)作用[J].中國中醫(yī)藥科技,2011,18(6):510-511.
[10] LIU YX,XU YF,LIN N,et al.High-Dose methotrexate(HD-MTX)used as an adjunct with other chemotherapeutics for the treatment of osteosarcoma[J].Cell Biochem Biophys,2015,71(2):1097-1104.
[11] 周俐斐,何福根,蘆柏震.中藥及復(fù)方防治化療性肝損傷的研究進展[J].中華中醫(yī)藥學刊,2014,32(6):1373-1375.
[12] 蔣沈君,劉云霞,楊潔文.柴胡垂盆湯預(yù)防骨肉瘤化療肝損傷43例療效觀察[J].浙江中醫(yī)雜志,2012,47(4):266.
[13] 劉云霞,徐葉峰,李夢蕓,等.清化復(fù)肝湯防治骨肉瘤甲氨蝶呤化療性肝損傷的臨床研究[J].浙江中醫(yī)雜志,2017,52(2):83-84.
[14] 姚勇偉,劉云霞,王翌慶,等.疏肝健脾方對骨肉瘤患者大劑量甲氨蝶呤化療后肝損傷的預(yù)防和修復(fù)作用觀察[J].中國中醫(yī)藥科技,2012,19(3):263-264.
[15] 王立明,方瑞英.10種中藥材對四氯化碳或半乳糖胺損傷的原代培養(yǎng)大鼠肝細胞的作用[J].浙江醫(yī)科大學學報,1994,23(3):109.
[16] 郭艷芳,胡文祥.幾種保肝降酶單味中藥研究進展[J].中華現(xiàn)代中醫(yī)學雜志,2007,3(2):116.
[17] PALMEIRA A,SOUSA E,VASCONCELOS MH,et al.Three decades of P-gp inhibitors:skimming through several generations and scaffolds[J].Curr Med Chem,2012,19(13):1946-2025.
[18] 王雅靈,閔大六.骨肉瘤化療耐藥分子機制的相關(guān)研究進展[J].癌癥進展,2016,14(4):311-315.
[19] 徐葉峰,劉云霞,沈敏鶴,等.中醫(yī)藥逆轉(zhuǎn)腫瘤多藥耐藥的策略及研究進展[J].中國中西醫(yī)結(jié)合雜志,2015,35(7):891-896.
[20] 王峰.槲皮素對人骨肉瘤細胞放射增敏作用研究[J].中藥藥理與臨床,2015,31(6):30-33.
[21] 江波,李燦,林清,等.槲皮素體內(nèi)外抑制人骨肉瘤細胞株143B增殖及其機制研究[J].實用藥物與臨床,2015,18(5):517-520.
[22] 肖揚,王萬春.姜黃素對人骨肉瘤細胞株/阿霉素多藥耐藥逆轉(zhuǎn)作用的實驗研究[J].衛(wèi)生研究,2011,40(1):103-106.
[23] 齊曉光,祁春艷,秦博宇,等.不同時機營養(yǎng)干預(yù)在化療后Ⅳ度骨髓抑制腫瘤患者中的療效比較[J].腫瘤防治研究,2018,45(1):29-31.
[24] 馮翠屏,卿晨.補血益氣類中藥對化療后骨髓抑制小鼠的骨髓保護作用研究[J].中國民族民間醫(yī)藥,2011,20(3):37-38.
[25] 秦麗,許成勇,王毓國,等.應(yīng)用益氣養(yǎng)血、健脾補腎法治療化療后骨髓抑制[J].中醫(yī)雜志,2017,58(12):1017-1020.
[26] 陳婧,劉云霞,楊潔文,等.八珍湯對骨肉瘤大劑量化療后骨髓的保護作用[J].浙江中醫(yī)雜志,2015,50(5):328-329.
[27] 陳慧彬,王茜,竇永起.補腎活血法與益氣補血法對環(huán)磷酰胺所致骨髓抑制小鼠骨髓基質(zhì)細胞生長及血清IL-6的影響[J].現(xiàn)代中西醫(yī)結(jié)合雜志,2014,23(3):232-234.
[28] JENKINS P,WELSH A.Computed tomography appearanceof early radiation injury to the lung:correlation with clinical and dosimetric factors[J].Int J Radiat Oncol Biol Phys,2011,81(1):97-103.[29] 李帥,劉云霞.中醫(yī)藥防治骨肉瘤肺轉(zhuǎn)移的研究進展[J].新中醫(yī),2017,49(11):137-141.
[30] 趙海恩,趙新文,周勇,等.骨肉瘤轉(zhuǎn)移的相關(guān)分子及臨床應(yīng)用研究進展[J].中國矯形外科雜志,2014,22(5):434-440.
[31] 李衛(wèi)東,花寶金.扶正固本治則中醫(yī)藥防治腫瘤復(fù)發(fā)轉(zhuǎn)移[J].中華中醫(yī)藥學刊,2012,30(3):509-511.
[32] 劉謙,王桂茹,吳荻.中西醫(yī)結(jié)合腫瘤防治新醫(yī)學模式簡析[J].中醫(yī)雜志,2015,56(13):1109-1111.
[33] 徐葉峰,劉云霞,陳婧,等.劉云霞主任中醫(yī)師分期論治骨肉瘤思想擷箐[J].新中醫(yī),2016,48(6):212-213.
[34] 張柘,吳劍,鄭勇,等.人參皂苷Rg3抗骨肉瘤LJH-OS細胞裸鼠移植瘤的作用及其對腫瘤血管生成擬態(tài)的影響[J].中華實驗外科雜志,2015,32(7):1569-1571.
相似文獻/References:
[1]于雅麗,王雷鳴.二氯乙酸鈉對人骨肉瘤MG63細胞增殖、凋亡和遷移的影響[J].中醫(yī)正骨,2017,29(01):11.
YU Yali,WANG Leiming.Effect of sodium dichloroacetate on cell proliferation,apoptosis and migration in human MG63 osteosarcoma cells[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(05):11.
[2]羅明星,劉丙根,羅文禮,等.保肢與截肢治療后骨肉瘤患者肢體功能及生活質(zhì)量的Meta分析[J].中醫(yī)正骨,2017,29(07):41.
LUO Mingxing,LIU Binggen,LUO Wenli,et al.Comparison of limb salvage and amputation on limb function and life quality of patients with osteosarcoma:a meta analysis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(05):41.
[3]羅漫麗,黃滿玉,李東升,等.多種血清腫瘤相關(guān)抗原自身抗體聯(lián)合檢測對骨肉瘤的診斷價值研究[J].中醫(yī)正骨,2021,33(04):32.
LUO Manli,HUANG Manyu,LI Dongsheng,et al.A study of the clinical value of combined detection on serum autoantibodies against tumor-associated antigens in the diagnosis of osteosarcomas[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2021,33(05):32.
[4]劉柏良,秦瑨,劉小榮,等.miR-27a參與骨肉瘤發(fā)生發(fā)展作用機制的研究進展[J].中醫(yī)正骨,2025,37(03):53.